Posted by Michael Wonder on 20 Sep 2022
FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in paediatric patients with localised, non-metastatic solid tumours
20 September 2022 - Today, the FDA approved sodium thiosulphate (Pedmark, Fennec Pharmaceuticals) to reduce the risk of ototoxicity associated with cisplatin in paediatric patients one month and older with localised, non-metastatic solid tumours.
Efficacy was evaluated in two multi-centre open-label, randomised controlled trials in paediatric patients undergoing treatment with cisplatin-based chemotherapy for cancer: SIOPEL 6 and COG ACCL043.
